Genitourinary Oncology Update 2021 SPOC
Genitourinary malignancies will account for approximately 20% of newly diagnosed cancers in 2021. Recent research advances in prostate, bladder, and kidney cancers utilizing new biomarkers and imaging tools, radiolabeled therapy, targeted therapy, immunotherapy and antibody-drug conjugates have led to new management approaches associated with significant improvements in patient outcomes.
These courses are intended for medical, radiation, and surgical oncologists, hematologists, advanced practice nurses, physician assistants, radiologic technologists, researchers, pharmacists, trainees, and others who are interested in care of patients with cancer in North Carolina.
- Describe new PSMA-directed approaches in the imaging and management of patients with prostate cancer.
- Review recent advances in systemic therapy for patients with muscle-invasive and metastatic bladder cancer.
- Discuss the use of immunotherapy and targeted therapy approaches in the management of advanced kidney cancer.
Matthew I. Milowsky, MDThe George Gabriel and Frances Gable Villere Distinguished Professor of Bladder and Genitourinary Cancer Research Section Chief, Genitourinary Oncology Co-Director, Urologic Oncology Program UNC Lineberger Comprehensive Cancer Center UNC School of Medicine University of North Carolina at Chapel Hill
Presenter Disclosure Information
Dr. Milowsky receives research support from Merck, Roche/Genentech, Bristol-Myers Squibb, As-tellas Pharma, Clovis Oncology, Inovio Pharmaceuticals, Mirati Therapeutics, Constellation Pharma-ceuticals, Syndax, Incyte, Amgen, Regeneron, Arvinas, Seagen, Johnson & Johnson. He has no other relevant financial relationships with commercial interests as defined by the ACCME.
This Non-Credit Course does NOT have accreditation for continuing education credits.
The course offers only general participation certificates.
- 1.00 Participation